GlassScriptPhysician profile
Jamie D Kemp
NPI 1699980854
$1,182.91
in general payments reported to CMS, 2019-2025
16 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $102 · 2021: $216 · 2022: $83.24 · 2023: $88.25 · 2024: $343 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $281.24 | 2019-2023 | Xarelto |
| Pfizer INC. | $182.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $148.23 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $133.39 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $126.00 | 2024 | |
| Boston Scientific Corporation | $49.81 | 2024-2025 | Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.80 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $42.26 | 2024-2025 | Uptravi, Opsumit |
| Octapharma USA, INC. | $30.83 | 2025 | Fibryga |
| Sanofi-Aventis U.S. LLC | $28.51 | 2019-2024 | |
| Lantheus Medical Imaging, INC. | $28.24 | 2020-2022 | |
| Daiichi Sankyo INC. | $22.21 | 2025 | Injectafer |
| Sanara Medtech INC. | $18.42 | 2023 | Celleraterx |
| Kiniksa Pharmaceuticals International, Plc | $16.61 | 2024 | Arcalyst |
| Novo Nordisk INC | $16.46 | 2024 | Rybelsus, Ozempic |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $14.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.